Endothelial cell dysfunction in systemic vasculitis: New developments and therapeutic prospects

Current Opinion in Rheumatology

Volumn 17, Issue 1, 2005, Pages 49-55

  Bacon, P A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Endothelial cell dysfunction; Systemic vasculitis

Indexed keywords

C REACTIVE PROTEIN; CD28 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN; NITRIC OXIDE; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY COMPLEX; CLINICAL RESEARCH; COMPLEMENT ACTIVATION; CORONARY ARTERY ANEURYSM; DISEASE COURSE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS;

CONNECTIVE TISSUE DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; VASCULITIS;

EID: 11344279663     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000149084.16639.b0     Document Type: Review

References (60)

1. Exley AR, Carruthers DM, Luqmani RA, et al.: Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997, 90:391-399.
2. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Bacon PA, Stevens RJ, Carruthers DM, et al.: Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 2002, 1:338-347.
4. Van Doornum S, McColl G, Jenkins A, et al.: Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003, 48:72-80.
5. Raza K, Thambyrajah J, Townend JN, et al.: Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000, 102:1470-1472.
6. Filer AD, Gardner-Medwin JM, Thambyrajah J, et al.: Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003, 62:162-167. This study both demonstrated ECD in two vascular beds of different vessel size and showed it to be present across a range of clinical syndromes.
7. Booth AD, Jayne DR, Kharbanda RK, et al.: Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004, 109:1718-1723. The authors used the most definitive test involving arterial infusions in a clinical physiology laboratory to confirm that ECD occurs in 1°SV, and they related this to disease activity. The improved EC function after therapy may well have related to the clinical remission achieved rather than to a specific effect of TNF blockade.
8. Booth AD, Wallace S, McEniery CM, et al.: Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004, 50:581-588. This study demonstrated increased arterial stiffness that also correlated with disease activity, showing that the altered EC function is associated with clinically relevant changes in blood vessel function. This study and [6,7•] clearly establish the frequency and relevance of EC dysfunction in adult 1°SV.
9. Dhillon R, Clarkson P, Donald AE, et al.: Endothelial dysfunction late after Kawasaki disease. Circulation 1996, 94:2103-2106.
10. Celermajer DS, Sorensen KE, Gooch VM, et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
11. Verma S, Buchanan MR, Anderson TJ: Endothelial function testing as a biomarker of vascular disease. Circulation 2003, 108:2054-2059.
12. Albisetti M, Chan AK, McCrindle BW, et al.: Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease. Blood Coagul Fibrinolysis 2003, 14:181-186.
13. Murakami H, Hirokami M, Hanawa N, et al.: Acetylcholine-induced coronary spasm with a history of Kawasaki disease: case report. Circ J 2003, 67:273-274.
14. Deng YB, Li TL, Xiang HJ, et al.: Impaired endothelial function in the brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C. Pediatr Infect Dis J 2003, 22:34-39. This interesting study confirmed that the presence of ECD in childhood vasculitis and its persistence for as long as 10 years after the acute stage occurred irrespective of the type of initial therapy. Despite this persistence, the impairment was not fixed because it improved rapidly with ascorbate infusion. This suggests that the chronic maintenance of ECD is an active metabolic process that we are ignorant of at present but that urgently needs unraveling.
15. Furuyama H, Odagawa Y, Katoh C, et al.: Altered myocardial flow reserve and endothelial function late after Kawasaki disease. J Pediatr 2003, 142:149-154. This study of Kawasaki disease at adult follow-up examined regional endothelial function in the coronary arteries directly, at catheterization, and correlated this with local myocardial flow reserve using a cold pressor test. Detailed analysis of multiple regions showed impairment according to both test results regardless of a history of aneurysm or current coronary anatomy. This firmly establishes a risk of late cardiovascular disease in all cases of Kawasaki disease.
16. Bacon PA, Raza K, Banks MJ, et al.: The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol 2002, 21:1-17.
17. Goodson NJ: Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002, 14:115-120.
18. Turesson C, O'Fallon WM, Crowson CS, et al.: Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003, 62:722-727.
19. Voskuyl AE, Hazes JM, Zwinderman AH, et al.: Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 2003, 62:407-413.
20. Hurlimann D, Forster A, Noll G, et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
21. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al.: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51:447-450. The effects of TNF blockade on EC function are relevant both to understanding the mechanisms of EC dysfunction and to controlling it. This paper suggests a complex response variable with time, as was also noted in an earlier abstract on 1°SV (see [47]). The late loss of benefit apparent at day 28 seems to contradict the data of Booth et al. [7•], but the latter assessed 1°SV patients at 12 weeks, after remission had been obtained. Further detailed serial assessments are needed to differentiate between the direct effects of therapy on EC function and the indirect benefits of suppressing disease activity.
22. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003, 114:647-652. This paper introduces the concept of genetic control of EC function, but it may actually act through the severity of RA in this case.
23. Vaudo G, Marchesi S, Gerli R, et al.: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004, 63:31-35.
24. Gerli R, Schillaci G, Giordano A, et al.: CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109:2744-2748. This interesting study relates EC function to a subset of T cells that are also seen in Wegener granulomatosis and primary atherosclerosis. These cells actively secrete TNF-α and are most likely to be involved in the late clinical stage with plaque instability.
25. Liuzzo G, Kopecky SL, Frye RL, et al.: Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999, 100:2135-2139.
26. Weyand CM, Goronzy JJ: T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999, 11:210-217.
27. Mueller A, Holl-Ulrich K, Feller AC, et al.: Immune phenomena in localized and generalized Wegener's granulomatosis. Clin Exp Rheumatol 2003, 21: S49-S54.
28. Lamprecht P, Bruhl H, Erdmann A, et al.: Differences in CCR5 expression on peripheral blood CD4+. Clin Immunol 2003, 108:1-7.
29. Komocsi A, Lamprecht P, Csernok E, et al.: Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am J Pathol 2002, 160:1717-1724.
30. Lamprecht P, Gross WL: Wegener's granulomatosis. Herz 2004, 29:47-56.
31. Kao AH, Sabatine JM, Manzi S: Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 2003, 15:519-527.
32. Asanuma Y, Oeser A, Shintani AK, et al.: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415. This paper discussed the risk factors associated with the accelerated atherosclerosis seen in SLE and provides evidence for the importance of disease-related factors.
33. Roman MJ, Shanker BA, Davis A, et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406. See [32•].
34. Piper MK, Heaton S, Gardner-Medwin J, et al.: A study of endothelial function in systemic lupus erythematosus. Lupus 2001, 10:49.
35. Lima DS, Sato El, Lima VC, et al.: Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002, 29:292-297.
36. Soep JB, Mietus-Snyder M, Malloy MJ, et al.: Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 2004, 51:451-457.
37. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al.: Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004, 50:151-159. This interesting study dissected the risk factors for both vascular stiffness and for carotid atheroma in SLE. The results suggest that the latter are associated with the classic risk factors seen in the population but that the former is more associated with SLE-specific variables. This could be interpreted as initiation of atherogenesis by disease-related impairment of EC function, with subsequent progression driven by classic factors.
38. Rajagopalan S, Somers EC, Brook RD, et al.: Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004, 103:3677-3683. This paper established that circulating EC particles (and precursors to replace damaged endothelium) are common in diseases with vascular inflammation and that the particles in turn affect endothelial function. Similar EC particles have been reported in acute coronary syndromes. See [54].
39. Woywodt A, Streiber F, de Groot K, et al.: Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003, 361:206-210. See [38•].
40. Brogan PA, Shah V, Brachet C, et al.: Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 2004, 50:927-936. See [38•].
41. Nakatani K, Takeshita S, Tsujimoto H, et al.: Circulating endothelial cells in Kawasaki disease. Clin Exp Immunol 2003, 131:536-540.
42. Clancy R, Marder G, Martin V, et al.: Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 2001, 44:1203-1208.
43. Chambers JC, Haskard DO, Kooner JS: Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol 2001, 37:517-520.
44. Orem A, Erturk M, Cimsit G, et al.: Effect of plasma from patients with Behcet's disease on the production of nitric oxide in cultured human umbilical vein endothelial cells. Med Princ Pract 2004, 13:35-38.
45. Probst K, Fijnheer R, Rothova A: Endothelial cell activation and hypercoagulability in ocular Behcet's disease. Am J Ophthalmol 2004, 137:850-857.
46. Vallance P, Collier J, Bhagat K: Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997, 349:1391-1392.
47. Stevens RJ, Gardner-Medwin J, Carruthers DM, et al.: Endothelial cell dysfunction improves acutely after infliximab. Rheumatology (Oxford) 2002, 41:24.
48. Amoli MM, Garcia-Porrua C, Llorca J, et al.: Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis. J Rheumatol 2003, 30:2019-2022.
49. Salvarani C, Casali B, Nicoli D, et al.: Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 2003, 48:3219-3223.
50. Wilkinson IB, Qasem A, McEniery CM, et al.: Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002, 105:213-217.
51. Amoli MM, Garcia-Porrua C, Calvino MC, et al.: Lack of association between endothelial nitric oxide synthase polymorphisms and Henoch-Schonlein purpura. J Rheumatol 2004, 31:299-301.
52. Kim JU, Chang HK, Lee SS, et al.: Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease and rheumatic diseases with vasculitis. Ann Rheum Dis 2003, 62:1083-1087.
53. Mallat Z, Hugel B, Ohan J, et al.: Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999, 99:348-353.
54. Mallat Z, Benamer H, Hugel B, et al.: Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000, 101:841 -843.
55. Isner JM, Losordo DW: Therapeutic angiogenesis for heart failure. Nat Med 1999, 5:491-492.
56. Aicher A, Heeschen C, Mildner-Rihm C, et al.: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003, 9:1370-1376.
57. Gokce N, Keaney JF Jr, Hunter LM, et al.: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002, 105:1567-1572.
58. Vita JA, Keaney JF Jr: Endothelial function: a barometer for cardiovascular risk? Circulation 2002, 106:640-642.
59. Filer AD, Nicholls D, Corston R, et al.: Takayasu arteritis and atherosclerosis: illustrating the consequences of endothelial damage. J Rheumatol 2001, 28:2752-2753.
60. Zaenker M, Aries PM, Herlyn K, et al.: Accelerated atherosclerosis in Wegener's granulomatosis (WG): a sonographic case-control study on intima media thickness. Arthritis Rheum 2002, 46:185.